
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.
Join Prof. Alexandra Papadopoulou as she reviews the multifaceted burden of children with EoE.

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.
Join Dr. Aceves and Ms. Ugras as they share their insights on how to identify potential patients with EoE and the importance of early diagnosis.
Learn from Drs. Buchheit and Wagenmann as they discuss key patient traits that predict disease recurrence in CRSwNP.
Join Professors Matthias Augustin and Sarina Elmariah for an engaging ADVENT symposium as they explore the pivotal role of type 2 inflammation in prurigo nodularis and chronic itch.
Learn how a food bolus impaction event can help identify a patient with EoE and the importance of multiple disease domains in assessing EoE.

New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares describes how IL-4 is the key cytokine involved in the initiation and perpetuation of Th2 cell responses and type 2 inflammation.